{
    "clinical_study": {
        "@rank": "131231", 
        "arm_group": {
            "arm_group_label": "1", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This study is to describe the safety and immunogenicity of 13vPnC in Indian adults 50 to 65\n      years of age and in Indian children 6 to 17 years of age."
        }, 
        "brief_title": "13-valent Pneumococcal Conjugate Vaccine Study in Adults and Children in India", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Prevention of Pneumonia and Invasive Disease Caused by the Serotypes in 13vPnC", 
        "condition_browse": {
            "mesh_term": "Pneumonia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Indian adults subjects between 50 and 65 years of age and indian children between 6 and\n        17years of age, determined by clinical judgment to be eligible for 13vPnC vaccination.\n\n        Exclusion Criteria:\n\n        Any contraindication to 13vPnC vaccination, vaccination with any pneumococcal vaccine\n        within the last year"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "6 Years"
        }, 
        "enrollment": {
            "#text": "1200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 10, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02034877", 
            "org_study_id": "B1851140"
        }, 
        "intervention": [
            {
                "arm_group_label": "1", 
                "description": "1 dose (0.5 mL/ pre-filed syringe) of 13vPnC administered at visit 1", 
                "intervention_name": "13-valent Pneumococcal conjugate vaccine", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "1", 
                "description": "10 mL of blood will be collected just before and approximately 1 month after vaccination.", 
                "intervention_name": "Blood sample collection", 
                "intervention_type": "Procedure"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "13-valent pneunococcal conjugate vaccine", 
            "pneumococcal disease prevention; safety and immunogenicity study"
        ], 
        "lastchanged_date": "May 14, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1851140&StudyName=13-valent%20pneumococcal%20conjugate%20vaccine%20study%20in%20adults%20and%20children%20in%20India%20"
        }, 
        "number_of_arms": "1", 
        "official_title": "A PHASE 4, OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO DESCRIBE THE SAFETY AND IMMUNOGENICITY OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 50 TO 65 YEARS OF AGE AND IN CHILDREN 6 TO 17 YEARS OF AGE IN INDIA", 
        "overall_contact": {
            "last_name": "Pfizer CT.gov Call Center", 
            "phone": "1-800-718-1021"
        }, 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "India: New Drug Advisory Committee", 
                "India: Drugs Controller General of India"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs) within approximately 1 month after 13vPnC administration.", 
                "measure": "The proportion of subjects reporting adverse events (AEs) and serious adverse events (SAEs) within approximately 1 month after 13vPnC administration.", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 1 month post vaccination"
            }, 
            {
                "description": "To describe the immune responses to the 13 pneumococcal serotypes induced by 13vPnC", 
                "measure": "Functional antibody titers as measured by serotype-specific opsonophagocytic activity (OPA) assays before and approximately 1 month after 13vPnC administration.", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 1 month post vaccination"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02034877"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}